If successful, the vaccine could protect women against ovarian cancer, which only around half of women survive long-term at the moment.

Scientists at the University of Oxford have just received funding to create the world's first vaccine for ovarian cancer, a deadly disease that affects thousands of people each year. The vaccine, called OvarianVax,

The American Cancer Society estimates that over 19,000 women will be newly diagnosed with ovarian cancer in 2024. As one of the more prevalent cancers among females, the desire for preventive measures against ovarian cancer is as strong as ever.

Most uterine cancers have excellent five-year survival rates—up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 cancer.

The world’s first ovarian cancer vaccine has been awarded research funding in the United Kingdom, marking the first step toward a groundbreaking preventive measure that scientists say could eliminate the disease entirely.

A first-ever ovarian cancer vaccine – currently being developed by the University of Oxford hopes to wipe off the deadly cancer – which kills thousands of women across the world yearly. According to scientists – the jab could be given to all women preventatively to eliminate the disease,